# Table of Contents

**FROM THE EDITOR**

Dealing with the “T” (testosterone) ............................................................. 78
If a patient feels better when taking testosterone supplementation, is it the “T” or is it a placebo effect?
Brian F. Mandell, MD, PhD

**1-MINUTE CONSULT**

What are the management considerations for venous thromboembolic events in patients with cirrhosis? 86
The authors review the current evidence on venous thromboembolic event (VTE) risk prediction in patients with cirrhosis, as well as VTE prophylaxis and anticoagulant therapy.
Marie M. Plante, MD, BSN, RN; Emily B. Wolf, MD; Razvan M. Chirila, MD

Does my patient have testosterone deficiency? 93
Diagnosis of testosterone deficiency requires the presence of relevant signs or symptoms along with biochemical evidence.
Andrew D. Shumaker, MD; Navid Leelani, DO; Bradley Roth; Prajit Khooblall, MD; Raevti Bole, MD; Scott D. Lundy, MD, PhD; Petar Bajic, MD

**REVIEW**

Diagnosis and management of pancreatic cystic lesions for the non-gastroenterologist 96
A summary of current guidelines from several organizations on the diagnosis and surveillance of pancreatic cystic lesions.
Arjun Chatterjee, MD; Tyler Stevens, MD, FACP, FASGE; Prabhleen Chahal, MD, FACP, FASGE

CONTINUED ON PAGE 77

---

**Upcoming Features**

- Artificial intelligence in clinical practice: A look at ChatGPT
- Multiple metabolic renal manifestations of a systemic disease
Hypertension and severe hyperreninemia in a young man

A 29-year-old man with blood pressure measurements of 152/118 mm Hg and 156/116 mm Hg at 2 separate clinic visits is started on combination antihypertensive therapy and undergoes evaluation for secondary causes of hypertension.

Joshua M. Leisring, MD; Jason Lyou, MD; Eshetu Obole, MD; Amy A. Yau, MD

Management of venous thromboembolism in patients with active cancer

The authors review the presentation and diagnosis of venous thromboembolism in patients with cancer and present an approach to treatment that aims to balance the bleeding risk from anticoagulation with the risk of recurrent thrombosis.

Heloni M. Dave, MBBS; Alok A. Khorana, MD, FACP, FASCO

von Willebrand disease: A guide for the internist

The pathophysiology of von Willebrand disease, its subtypes, common presentations of each subtype, diagnostic testing, and management of clinical manifestations of the disease are reviewed.

Varinder Kaur, MD; Omar Elghawy, MD; Saarang Deshpande, MD; David Riley, MD

Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?

Taher Modarressi, MD

In Reply: Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?

Pooja Prasad, MD; Megha Prasad, MD

Surgical and procedural management of benign prostatic hyperplasia

Sameer Gadani, MD; Ihab Haddadin, MD; Justin Guan, MD; Michael Bergen, MD; Abraham Levitin, MD

In Reply: Surgical and procedural management of benign prostatic hyperplasia

Ayodeji E. Sotimehin, MD; Bradley C. Gill, MD, MS

Correction

In the January 2024 issue, the article “When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?” by Badwan OZ et al [Cleve Clin J Med 2024; 91(1): 47–51. doi:10.3949/ccjm.91a.23034] contained an error in Figure 1.